Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumateperone in pediatric patients with Autism Spectrum Disorder
NCT06557902Phase 1Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- May 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lumateperone in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Intra-Cellular Therapies. Primary endpoints: Maximum Observed Plasma Concentration at Day 5, Time to Maximum Plasma Concentration at Day 5 and 1 more. Started May 2024; status: completed.
02
Drugs
lumateperone
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06557902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06557902.